This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Arcus (RCUS) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Arcus (RCUS) is expected to provide an update on its pipeline with the release of its first-quarter 2019 results
Zoetis (ZTS) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Zoetis (ZTS) is expected to provide updates on the pipeline, when it reports first-quarter 2019 results on May 2.
Teva (TEVA) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Pricing erosion in U.S. generics market and rapid erosion in sales of Copaxone are likely to hurt Teva's (TEVA) sales in Q1.
Will HIV Franchise Sales Drive Gilead's (GILD) Q1 Earnings?
by Zacks Equity Research
Investors are expected to focus on the HIV franchise and other pipeline updates, when Gilead (GILD) reports first-quarter results.
Is a Beat in Store for Glaxo (GSK) This Earnings Season?
by Zacks Equity Research
Strong sales of Glaxo's (GSK) Vaccines segment is likely to drive the top line in the first quarter.
Can Keytruda Drive Merck's (MRK) Q1 Earnings and Sales?
by Zacks Equity Research
Merck's (MRK) relatively newer products like Keytruda, Gardasil and Bridion are likely to drive first-quarter sales. However, genericization of key drugs and increasing competition are concerns.
Exelixis (EXEL) to Report Q1 Earnings: What's in Store?
by Zacks Equity Research
Exelixis' (EXEL) first-quarter 2019 results are expected to benefit from increase in Cabometyx sales. Investors will focus on other pipeline updates as well.
Lannett (LCI) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Lannet (LCI) will release fiscal third-quarter earnings and is expected to provide an update on product launches
Eli Lilly (LLY) to Report Q1 Earnings: What's in the Cards?
by Kinjel Shah
Eli Lilly and Company's (LLY) new drugs like Trulicity, Taltz and Jardiance are performing well. Let's see if these along with its older products lead to an earnings beat for the company in Q1.
Novartis (NVS) Q1 Earnings Beat Estimates, Revenues Up Y/Y
by Zacks Equity Research
Novartis (NVS) beats on Q1 earnings, sales marginally miss estimates.
Alexion (ALXN) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Alexion's (ALXN) first-quarter 2019 results are likely to gain on solid performance of lead drug, Soliris. Investors will also focus on updates on pipeline candidates.
What's in Store for Celgene Corporation (CELG) Q1 Earnings?
by Zacks Equity Research
Investors are looking forward to Revlimid's performance and updates on the impending acquisition agreement with Bristol-Myers, when Celgene Corporation (CELG) reports Q1 results.
Are Investors Undervaluing GlaxoSmithKline (GSK) Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
What's in Store for Bayer (BAYRY) This Earnings Season?
by Zacks Equity Research
Bayer (BAYRY) is expected to provide pipeline updates along with its first-quarter results.
Will Bristol-Myers (BMY) Disappoint This Earnings Season?
by Zacks Equity Research
Performance of Opdivo and the impending acquisition of Celgene Corporation will be key areas of focus for the investors, when Bristol-Myers (BMY) reports first-quarter results.
Clovis Focuses on Rubraca Label Expansion, Competition Stiff
by Zacks Equity Research
Although sales of Clovis' (CLVS) Rubraca improved in the fourth quarter of 2018, the drug may face significant competition going forward. Clovis is also evaluating Rubrca for other cancer indications.
Emergent's (EBS) Chikungunya Vaccine Positive in Phase II Study
by Zacks Equity Research
Emergent (EBS) posts interim data from the phase II study on its chikungunya vaccine, CHIKV-VLP. The candidate generates positive immune response against the chikungunya virus.
Axsome's AXS-05 Meets Goal in Phase II Study, Shares Up
by Zacks Equity Research
Axsome's (AXSM) mid-stage candidate, AXS-05, achieves the primary endpoint in a phase II study as a smoking cessation treatment. Shares rise.
Novartis' (NVS) BLA for Ophthalmology Drug Accepted by FDA
by Zacks Equity Research
The FDA accepts Novartis' (NVS) BLA seeking approval for brolucizumab for the treatment of wet AMD.
Clovis Stalls Mid-Stage Rubraca Study for Bladder Cancer
by Zacks Equity Research
Clovis Oncology (CLVS) halts mid-stage bladder cancer study evaluating Rubraca monotherapy. It is unlikely to provide meaningful clinical benefit as reviewed by an independent data monitoring committee.
Merck's Keytruda Gets FDA Nod for Expanded Lung Cancer Group
by Zacks Equity Research
Merck (MRK) gets FDA approval to include overall survival data from the KEYNOTE-042 study on Keytruda's label.
Pharma Stock Roundup: AZN, MRK, GSK Get Regulatory Approvals, Sandoz Inks New Deal
by Kinjel Shah
Glaxo (GSK) gets FDA approval for a new HIV medicine, Dovato. AstraZeneca (AZN)/Merck's (MRK) Lynparza gets approval in EU for metastatic breast cancer.
Novartis to Market Rizmoic Through Sandoz, Spins Off Alcon
by Zacks Equity Research
Novartis' (NVS) Sandoz signs an agreement with Japanese company, Shionogi, to commercialize constipation drug in key European markets.
AstraZeneca/Merck's Lynparza Wins EU Nod for Breast Cancer
by Zacks Equity Research
AstraZeneca (AZN) and Merck gain an EU approval for Lynparza as a monotherapy for treating HER2-negative locally-advanced/metastatic breast cancer.
Emergent's (EBS) Strong Vaccine Portfolio to Fuel Growth
by Zacks Equity Research
Emergent's (EBS) vaccine portfolio looks promising. The company's recent acquisitions also bode well for growth.